10-Q · May 14, 2026
GlucoTrack, Inc. reported a notable decrease in net loss to $4.3 million for Q1 2026, down from $6.8 million year-over-year. The company continues to focus on research and development expenditures, amounting to $2.1…
Earnings analysis · 10-Q
GCTK earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
This 10-Q presents a pre-revenue clinical-stage company with sharply higher losses, $53,186 of cash, a $6,846,937 working-capital deficit, and $3,624,474 of six-month operating cash burn. Liquidity and Nasdaq listing…
Read full summary
This 10-Q presents a pre-revenue clinical-stage company with sharply higher losses, $53,186 of cash, a $6,846,937 working-capital deficit, and $3,624,474 of six-month operating cash burn. Liquidity and Nasdaq listing risks intensified, with the company acknowledging substantial doubt about its ability to continue as a going concern and facing both bid-price and $2,500,000 stockholders’ equity deficiencies. FDA pathway work on LT-100 is progressing, but the product remains unapproved and the company’s controls contain unresolved material weaknesses.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Losses expanded sharply year over year
The company reported net losses of $5,889,447 for the three months and $8,098,087 for the six months ended June 30, 2026, compared with $2,639,139 and $3,041,536, respectively, in the prior-year periods. This represents year-over-year loss increases of approximately 123% and 166%.
-
No product revenue yet
The company has not generated revenue from product sales and states that it does not expect revenue from LT-100 in the near future. The filing therefore provides no meaningful revenue, gross-margin, operating-margin, or segment-growth trend.
-
Severe liquidity pressure
Cash and cash equivalents were only $53,186 as of June 30, 2026, versus total current liabilities of $9,136,120 and total current assets of $2,289,183, producing a working-capital deficit of $6,846,937.
-
Operating cash burn and going concern
Net cash used in operating activities was $3,624,474 for the six months ended June 30, 2026. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months from the filing date.
-
FDA pathway work continued
Management held a Type C meeting with the FDA in May 2026 regarding LT-100 and is evaluating whether to simplify administration from up to 15 intradermal injections per treatment visit to a single subcutaneous injection.
-
Control remediation underway
Management has begun remediation of internal-control weaknesses by hiring accounting personnel, engaging third-party valuation and technical-accounting experts, and implementing Oracle NetSuite. The company stated that remediation is expected to continue during fiscal year 2026.
What to watch
-
Nasdaq delisting risk escalated
Nasdaq issued a May 11, 2026 Staff Determination to delist the common stock after its bid price remained below $1.00 for 30 consecutive business days from March 27 through May 8, 2026. Nasdaq also cited failure to meet the $2,500,000 minimum stockholders’ equity requirement, and the company reported a $6,740,718 total stockholders’ deficit as of June 30, 2026.
-
Additional capital is urgently required
The company had only $53,186 of cash and a $6,846,937 working-capital deficit as of June 30, 2026, while net cash used in operating activities was $3,624,474 for the first six months. The filing states that these conditions raise substantial doubt about continuing as a going concern for at least twelve months.
-
Material weaknesses remain unresolved
As of June 30, 2026, disclosure controls and procedures were concluded to be not effective. Material weaknesses include general IT controls, insufficient accounting personnel, and inadequate segregation of duties; management cautioned that remediation initiatives may not fully address the weaknesses.
-
Merger creates additional listing hurdle
The July 30, 2026 Nasdaq determination classified the Lokahi business combination as a change of control, requiring the post-transaction entity to satisfy all initial Nasdaq listing criteria. There is no assurance that the initial listing application will be approved or that the company will regain compliance with the Bid Price Rule and $2,500,000 equity requirement.
-
LT-100 rights carry cash and legal risk
The company paid $3 million in cash and assumed certain liabilities under the April 2026 settlement that transferred rights to the LT-100 program. The filing warns that assumed liabilities may exceed current estimates and consume cash otherwise available for development.
-
Clinical and regulatory execution risk
LT-100 remains unapproved by the FDA, and the company has not completed a pivotal trial. The proposed change from up to 15 intradermal injections to one subcutaneous injection may require additional development, and the company states that product revenue may not occur for several years, if ever.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management stated that it expects substantial and increasing operating losses over the next several years, will require substantial additional capital, and expects to finance cash needs through equity or debt financings, third-party funding, and collaboration or licensing arrangements.
Earlier filings 4
10-K · March 30, 2026
Glucotrack (GCTK) is a clinical-stage medical device company focused on an implantable continuous blood glucose monitor (Glucotrack CBGM). The 2025 10-K documents technical progress — a completed first-in-human acute…
10-Q · November 14, 2024
Glucotrack reported no revenue and continues to burn cash: a net loss of $5,087 for the three months ended September 30, 2024 (vs $2,223 in Q3 2023) and a nine‑month loss of $12,503 (vs $4,685). Cash and cash…
10-Q · May 15, 2024
Glucotrack reported no revenue and a widening quarterly loss as it ramped R&D and recognized a small operating lease. Net loss for the three months ended March 31, 2024 was $2,927 (vs. $1,286 prior year) and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.